Modified-FOLFIRINOX Beneficial in Resected Pancreatic Cancer

Share this content:
Modified-FOLFIRINOX Beneficial in Resected Pancreatic Cancer
Modified-FOLFIRINOX Beneficial in Resected Pancreatic Cancer

WEDNESDAY, Dec. 19, 2018 (HealthDay News) -- For patients with resected pancreatic cancer, adjuvant therapy with a modified regimen of chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX), compared with gemcitabine, results in significantly longer survival, according to a study published in the Dec. 20 issue of the New England Journal of Medicine.

Thierry Conroy, M.D., from the Institut de Cancérologie de Lorraine in Vandoeuvre-lès-Nancy, France, and colleagues randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive either a modified FOLFIRINOX regimen or gemcitabine for 24 weeks.

The researchers found median disease-free survival rates of 21.6 and 12.8 months in the modified-FOLFIRINOX and gemcitabine groups, respectively, during a median follow-up of 33.6 months (stratified hazard ratio for cancer-related event, second cancer, or death, 0.58). At three years, disease-free survival rates were 39.7 and 21.4 percent in the modified-FOLFIRINOX and gemcitabine groups, respectively. Median overall survival was 54.4 and 35.0 months, respectively, in the modified-FOLFIRINOX and gemcitabine groups (stratified hazard ratio for death, 0.64). At three years, overall survival rates were 63.4 and 48.6 percent in the modified-FOLFIRINOX and gemcitabine groups, respectively. Grade 3 or 4 adverse events occurred in 75.9 and 52.9 percent of patients in the modified-FOLFIRINOX and gemcitabine groups, respectively.

"This trial represents the culmination of more than a decade of careful work that initially established FOLFIRINOX as a standard treatment for advanced pancreatic cancer," write the authors of an accompanying editorial.

Several authors disclosed financial ties to the pharmaceutical industry; the study was partially funded by R&D Unicancer, which received a grant from Chugai Pharmaceutical.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Head Says Feds May Intervene to Cut Vaccine Exemptions

FDA Head Says Feds May Intervene to Cut ...

If states do not change lax vaccine laws, federal authorities may be forced to take action

New Kaiser Permanente Medical School Plans to Waive Tuition

New Kaiser Permanente Medical School Plans to Waive ...

School will waive all tuition for the full four years of school for its first five classes

Experimental Test May Quickly Diagnose Sepsis

Experimental Test May Quickly Diagnose Sepsis

Microelectrode device analyzes a patient's blood, provides results in as quickly as 2.5 minutes

is free, fast, and customized just for you!




Already a member?

Sign In Now »